bgb-30813 + tislelizumab

BGB-30813 + tislelizumab is an investigational combination therapy developed by BeiGene for the treatment of advanced or metastatic solid tumors[1][3]. **BGB-30813** is an orally administered, selective small-molecule inhibitor of Diacylglycerol Kinase Zeta (DGKζ), an intracellular checkpoint that negatively regulates T-cell activation. By inhibiting DGKζ, BGB-30813 is intended to amplify T-cell-mediated anti-tumor immunity. **Tislelizumab** (brand name Tevimbra) is a monoclonal antibody targeting programmed cell death protein 1 (PD-1), a well-established immune checkpoint, blocking its interaction with PD-L1 and PD-L2 to enhance anti-tumor T-cell responses. The combination is designed to overcome resistance to current immunotherapies, particularly checkpoint inhibitors, and is being investigated in a Phase 1 clinical trial in patients with advanced solid tumors who have failed standard therapies, including prior checkpoint inhibitor regimens[1][3].